Cytokine release syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cytokine release syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Dasatinib for Preventing Side Effects in Patients with Relapsed or Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel Therapy https://clinicaltrials.eu/trial/study-on-dasatinib-for-preventing-side-effects-in-patients-with-relapsed-or-refractory-multiple-myeloma-receiving-idecabtagene-vicleucel-therapy/ Wed, 29 Apr 2026 14:56:59 +0000 https://clinicaltrials.eu/trial/study-on-dasatinib-for-preventing-side-effects-in-patients-with-relapsed-or-refractory-multiple-myeloma-receiving-idecabtagene-vicleucel-therapy/ This clinical trial is focused on studying a treatment for patients with relapsed or treatment-resistant multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The study involves two medications: idecabtagene vicleucel and dasatinib. Idecabtagene vicleucel is a type of cell therapy where a patient’s own T cells, a kind of white blood cell, are modified to better recognize and attack cancer cells. This therapy is known as CAR-T cell therapy. Dasatinib is a medication that is being tested to see if it can help prevent side effects associated with CAR-T cell therapy, specifically a condition called cytokine release syndrome (CRS), which can occur when the immune system becomes overly active.

The purpose of this study is to evaluate the safety and effectiveness of dasatinib in preventing CRS in patients receiving idecabtagene vicleucel therapy. Participants in the study will receive dasatinib as a preventive measure while undergoing treatment with idecabtagene vicleucel. The study will monitor the occurrence and severity of CRS and other potential side effects over a period of time. The trial will also assess how well patients respond to the treatment and their overall health outcomes.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how the treatment affects their condition. The study aims to provide valuable insights into improving the management of side effects in patients undergoing CAR-T cell therapy for multiple myeloma.

]]>